These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 22817631)

  • 1. US FDA outreach to the regenerative medicine community: challenges and opportunities.
    Whittlesey KJ; Witten C
    Regen Med; 2012 Jul; 7(4):595-603. PubMed ID: 22817631
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FDA faces regulatory challenges with new approaches to medicine.
    Roehr B
    BMJ; 2014 Feb; 348():g1530. PubMed ID: 24531207
    [No Abstract]   [Full Text] [Related]  

  • 3. Concise Review: The U.S. Food and Drug Administration and Regenerative Medicine.
    Witten CM; McFarland RD; Simek SL
    Stem Cells Transl Med; 2015 Dec; 4(12):1495-9. PubMed ID: 26494784
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluating the FDA regenerative medicine framework: opportunities for stakeholders.
    Richardson E; Akkas F; Master Z
    Regen Med; 2020 Jul; 15(7):1825-1832. PubMed ID: 32815780
    [No Abstract]   [Full Text] [Related]  

  • 5. Considerations for tissue-engineered and regenerative medicine product development prior to clinical trials in the United States.
    Lee MH; Arcidiacono JA; Bilek AM; Wille JJ; Hamill CA; Wonnacott KM; Wells MA; Oh SS
    Tissue Eng Part B Rev; 2010 Feb; 16(1):41-54. PubMed ID: 19728784
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FDA's expanding postmarket authority to monitor and publicize food and consumer health product risks: the need for procedural safeguards to reduce "transparency" policy harms in the post-9/11 regulatory environment.
    Roller ST; Pippins RR; Ngai JW
    Food Drug Law J; 2009; 64(3):577-98. PubMed ID: 19999646
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advancing regulatory science to bring novel medical devices for use in emergency care to market: the role of the Food and Drug Administration.
    Scully CG; Forrest S; Galeotti L; Schwartz SB; Strauss DG
    Ann Emerg Med; 2015 Apr; 65(4):400-3. PubMed ID: 25128009
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Food and Drug Administration, regenerative sciences, and the regulation of autologous stem cell therapies.
    von Tigerstrom B
    Food Drug Law J; 2011; 66(4):479-506, i. PubMed ID: 24505826
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The history and contemporary challenges of the US Food and Drug Administration.
    Borchers AT; Hagie F; Keen CL; Gershwin ME
    Clin Ther; 2007 Jan; 29(1):1-16. PubMed ID: 17379043
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Food and Drug Administration requirements for testing and approval of new radiopharmaceuticals.
    Harapanhalli RS
    Semin Nucl Med; 2010 Sep; 40(5):364-84. PubMed ID: 20674596
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The government's role in advancing regenerative medicine and tissue engineering - science, safety, and ethics.
    Smith DS
    Periodontol 2000; 2006; 41():16-29. PubMed ID: 16686924
    [No Abstract]   [Full Text] [Related]  

  • 12. Governmental Regulations and Increasing Food and Drug Administration Oversight of Regenerative Medicine Products: What's New in 2020?
    Fang WH; Vangsness CT
    Arthroscopy; 2020 Oct; 36(10):2765-2770. PubMed ID: 32442713
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expediting Drug Development: FDA's New Regenerative Medicine Advanced Therapy Designation.
    Vaggelas A; Seimetz D
    Ther Innov Regul Sci; 2019 May; 53(3):364-373. PubMed ID: 29895180
    [TBL] [Abstract][Full Text] [Related]  

  • 14. US FDA perspective on challenges in co-developing in vitro companion diagnostics and targeted cancer therapeutics.
    Philip R; Carrington L; Chan M
    Bioanalysis; 2011 Feb; 3(4):383-9. PubMed ID: 21338257
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The FDA's role in medical device clinical studies of human subjects.
    Saviola J
    J Neural Eng; 2005 Mar; 2(1):S1-4. PubMed ID: 15876645
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Delegations of authority and organization; revised organization. Food and Drug Administration. Final rule.
    Fed Regist; 1982 Mar; 47(41):8761-3. PubMed ID: 10254381
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FDA challenges stem-cell clinic.
    Cyranoski D
    Nature; 2010 Aug; 466(7309):909. PubMed ID: 20725009
    [No Abstract]   [Full Text] [Related]  

  • 18. Awareness of the role of science in the FDA regulatory submission process: a survey of the TERMIS-Americas membership.
    Johnson PC; Bertram TA; Carty NR; Hellman KB; Tawil BJ; Van Dyke M
    Tissue Eng Part A; 2014 Jun; 20(11-12):1565-82. PubMed ID: 24665855
    [TBL] [Abstract][Full Text] [Related]  

  • 19. One hundred years of drug regulation: where do we go from here?
    Woosley RL
    Annu Rev Pharmacol Toxicol; 2013; 53():255-73. PubMed ID: 23072378
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regenerative medicine, resource and regulation: lessons learned from the remedi project.
    Ginty PJ; Rayment EA; Hourd P; Williams DJ
    Regen Med; 2011 Mar; 6(2):241-53. PubMed ID: 21391857
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.